Saturday, October 31, 2026

Mozambique Assumes SADC PF Presidency

Moses Magadza

December 12, 2018

The Speaker of the National Assembly of Mozambique, Hon. Veronica Nataniel Macamo Dlhovo (standing) speaks after being elected unopposed as President of SADC PF. The Speaker of the National Assembly of Eswatini, Hon Petros Mavimbela was also elected unopposed. Vice President of SADC PF (left) and Acting Secretary General of the SADC PF listen in during the 44th Plenary Assembly Session in Maputo, Mozambique. Photo: Moses Magadza/SADC PF
MAPUTO (ViaNews) - The Speaker of the National Assembly of Mozambique, Hon. Veronica Nataniel Macamo Dlhovo, and the Speaker of the National Assembly of Eswatini, Hon Petros Mavimbela, were elected unopposed as President and Vice President of the SADC PF (Southern African Development Community Parliamentary Forum), respectively, last week. The two lawmakers were elected at the end of the 44th Plenary Assembly Session of the SADC PF which the National Assembly of Mozambique hosted. They will serve the Forum for two years having taken over from the Speaker of the National Assembly of Angola, Hon Fernando da Piedade Dias Dos Santos and Senator Monica Mutsvangwa of Zimbabwe, who served as President and Vice President of the Forum from 2016 to 2018. [caption id="attachment_5828" align="aligncenter" width="696"]The Speaker of the National Assembly of Mozambique, Hon. Veronica Nataniel Macamo Dlhovo (standing) speaks after being elected unopposed as President of SADC PF. The Speaker of the National Assembly of Eswatini, Hon Petros Mavimbela was also elected unopposed. Vice President of SADC PF (left) and Acting Secretary General of the SADC PF listen in during the 44th Plenary Assembly Session in Maputo, Mozambique. Photo: Moses Magadza/SADC PF The Speaker of the National Assembly of Mozambique, Hon. Veronica Nataniel Macamo Dlhovo (standing) speaks after being elected unopposed as President of SADC PF. The Speaker of the National Assembly of Eswatini, Hon Petros Mavimbela was also elected unopposed. Vice President of SADC PF (left) and Acting Secretary General of the SADC PF listen in during the 44th Plenary Assembly Session in Maputo, Mozambique. Photo: Moses Magadza/SADC PF[/caption] Hon Dos Santos and his Executive Committee are credited for managing to put the issue of the transformation of the SADC PF into SADC Regional Parliament on the agenda of the 38th SADC Summit for Heads of State and Government. In a major breakthrough, the Summit warmed up to the idea of transforming the Forum and accepted it in principle before referring the issue to national Parliaments for further discussion with a clear timeline. The challenge for the new leaders would be to build on the momentum created by their predecessors. It seems they have hit the ground running. The new SADC PF President said immediately after her election that she would convene an urgent meeting to discuss how the good work done under the previous Executive Committee can be taken forward. Another priority for the new leadership would be to help operationalize the SADC PF’s 2019 - 2023 Strategic Plan. The 44th Plenary adopted a motion calling on the Forum to allow five Members of the previous Executive Committee to continue serving in the current one, albeit without voting powers. The idea is to maintain momentum, enable continuity, and preserve institutional memory.

Categories

Tags

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com